Design,synthesis, and biological evaluation of pyrimidine derivatives as potential inhibitors of human calcium/calmodulin‐dependent protein kinase IV |
| |
Authors: | Parvez Khan Mohd. Tarique Jitendra Kumar Syed Mumtazuddin Shahzaib Ahamad Asimul Islam Faizan Ahmad Nasimul Hoda Md. Imtaiyaz Hassan |
| |
Affiliation: | 1. Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India;2. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India;3. Department of Chemistry, Jamia Millia Islamia, New Delhi, India;4. Department of Chemistry, B.R. Ambedkar Bihar University, Muzaffarpur, Bihar, India;5. Department of Biotechnology, College of Engineering and Technology, IFTM, Moradabad, India |
| |
Abstract: | Calcium/calmodulin‐dependent protein kinase IV (CAMKIV ) is a multifunctional Ser/Thr kinase, associated with cerebral hypoxia, cancer, and neurodegenerative diseases. Here, we report design, synthesis, and biological evaluation of seven pyrimidine‐substituted novel inhibitors of CAMKIV . We successfully synthesized and extensively characterized (ESI ‐MS , 1H NMR , and 13C NMR studies) seven compounds that are showing appreciable binding affinity to the CAMKIV . Molecular docking and fluorescence binding studies revealed that compound 1 is showing very high binding free energy (ΔG = ?11.52 kcal/mol) and binding affinity (K = 9.2 × 1010 m ?1) to the CAMKIV . We further performed MTT assay to check the cytotoxicity and anticancer activity of these compounds. An appreciable IC 50 (39 μm ) value of compound 1 was observed on human hepatoma cell line and nontoxic till the 400 μm on human embryonic kidney cells. To ensure anticancer activity of all these compounds, we further performed propidium iodide assay to evaluate cell viability and DNA content during the cell cycle. We found that compound 1 is again showing a better anticancer activity on both human hepatoma and human embryonic kidney cell lines. |
| |
Keywords: | anticancer activity calcium/calmodulin‐dependent protein kinase IV drug design and discovery high‐affinity ligands molecular docking |
|
|